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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive fatal neurodegenerative disease, involving both
upper and lower motor neurons. The disease is induced by multifactorial pathologies, and as such, it requires a
multifaceted therapeutic approach. CXCR4, a chemokine receptor widely expressed in neurons and glial cells and its
ligand, CXCL12, also known as stromal-cell-derived factor (SDF1), modulate both neuronal function and apoptosis
by glutamate release signaling as well as hematopoietic stem and progenitor cells (HSPCs) migration into the blood
and their homing towards injured sites. Inhibition approaches towards the CXCR4/CXCL12 signaling may result in
preventing neuronal apoptosis and alter the HSPCs migration and homing. Such inhibition can be achieved by
means of treatment with AMD3100, an antagonist of the chemokine receptor CXCR4.
Methods: We chronically treated male and female transgenic mice model of ALS, SOD1G93A mice, with AMD3100.
Mice body weight and motor function, evaluated by Rotarod test, were recorded once a week. The most effective
treatment regimen was repeated for biochemical and histological analyses in female mice.
Results: We found that chronic administration of AMD3100 to SOD1G93A mice led to significant extension in mice
lifespan and improved motor function and weight loss. In addition, the treatment significantly improved microglial
pathology and decreased proinflammatory cytokines in spinal cords of treated female mice. Furthermore, AMD3100
treatment decreased blood-spinal cord barrier (BSCB) permeability by increasing tight junction proteins levels and
increased the motor neurons count in the lamina X area of the spinal cord, where adult stem cells are formed.
Conclusions: These data, relevant to the corresponding disease mechanism in human ALS, suggest that blocking
CXCR4 by the small molecule, AMD3100, may provide a novel candidate for ALS therapy with an increased safety.
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Background
Amyotrophic lateral sclerosis (ALS) is a progressive
fatal neurodegenerative disease involving both upper
and lower motor neurons [1]. Although the pathology
of ALS has not yet been understood, several studies
have obtained evidence including increased levels of
proinflammatory cytokines and proliferation and acti-
vation of glial cells involvement in the disease progres-
sion. Microglia cells play a critical role as resident
immunocompetent and phagocytic cells within the cen-
tral nervous system. Microglial activation is associated
with increased nitric oxide, reactive oxygen species,
and proinflammatory cytokines, such as TNFα and IL-1β,
which could generate a neuroinflammatory environment
[2, 3]. Recent studies indicate that microglial cells could
be involved in the initiation and propagation of motor
neuronal cell damage in ALS [4–9]. Indeed, microglial ac-
tivation was also shown to have a major role in later dis-
ease progression, not only in disease onset and early phase
of disease progression in mutant SOD1 (mSOD1) mice
[10]. Therefore, targeted therapy to microglia may be an
effective strategy for ALS treatment.
Recently, the anti-inflammatory effect of bone marrow-
derived stem cells (BMSCs) has generated a great deal of
interest. Studies have shown that BMSCs can regulate im-
mune cell proliferation, such as shown in animal models
of Parkinson disease, cerebral ischemia, Krabbe’s disease,
and ALS, in which administration of BMSCs attenuated
inflammation and improved motor function [11–15].
Transplantation of BMSCs has been suggested as a
potential therapeutic approach to prevent neurodegen-
erative diseases; however, it remains problematic due to
issues of engraftment, potential toxicities, and other
different factors [16]. An alternative therapeutical ap-
proach is pharmacological-induced recruitment of en-
dogenous BMSCs into an injured tissue by systemic
administration of chemokines. Chemokines are a family
of small secreted proteins with variety of immune and
neural functions, such as regulation of leukocyte traf-
ficking, organization of the hematopoetic/lymphopoetic
system, and angiogenesis. Chemokines and their recep-
tors in the central nervous system (CNS) are relevant
for the understanding of brain physiology and patho-
physiology and may lead to the development of targeted
treatments for neurodegenerative diseases [17].
CXCR4 is a chemokine receptor, widely expressed in
neurons and glial cell. Its ligand, CXCL12, also known as
stromal-cell-derived factor (SDF1), modulates both neur-
onal function and apoptosis by glutamate release signaling
[18] as well as hematopoietic stem and progenitor cells
(HSPCs) migration into the blood and their homing in in-
jured sites [19]. Inhibition approaches towards the
CXCR4/CXCL12 signaling might result in preventing the
toxic cascade of glutamate release from glial cells and
neuronal apoptosis and alter the HSPCs migration and
homing. Such inhibitor is AMD3100 (Mozobil, plerixafor),
a FDA-approved bicyclam molecule that specifically
blocks CXCL12 binding to CXCR4. AMD3100 was previ-
ously shown to rapidly mobilize hematopoietic stem and
progenitor cells (HSPCs) from the bone marrow into
the circulating blood for transplantation in patients
with hematological malignancies such as non-Hodgkin’s
lymphoma or multiple myeloma [19, 20].
Inhibition of CXCR4/CXCL12 signaling may also
regulate blood-central nervous system-barrier (BCNSB)
integrity through tight junction proteins [21]. In human
ALS and rodents expressing SOD1 mutations were re-
ported pathological changes in the BCNSB composed
of the blood-brain barrier (BBB), blood-spinal cord
barrier (BSCB), and blood-cerebrospinal fluid barrier
(BCSFB). All three barriers have an essential role in
modulating CNS homeostasis, due to the composition
of the microvasculature–capillaries formed by endothe-
lial cells. According to this unique composition, break-
down of the BSCB was proposed to have a primary role
in the early-stage disease pathogenesis and its rehabili-
tation might slow down disease progression [22]. Early
studies of serum immunoglobulin (IgG) leakage re-
ported microhemorrhages and BSCB breakdown in the
spinal cord of ALS patients and mSOD1 transgenic
mice even before motor neurons degeneration, as evi-
dent from the mouse model [23–25].
The breakdown of the BSCB in ALS mice is followed
by measuring of the levels of various tight junction pro-
teins including ZO-1, occludin, and claudin-5 between
endothelial cells [23]. The loss of these tight junction
proteins in the microvasculature is mediated by various
proinflammatory cytokines such as monocyte chemo-
attractant protein-1 (MCP1, also known as CCL2),
TNF-α, IL-1β, and IFN-γ [23]. SOD1 mutants mediate
endothelial damage even before motor neuron death
and hypoxia and inflammation lead to increased BSCB
permeability and disruption suggesting that early inter-
vention in treatment of the disease may have beneficial
effect in rehabilitation of BSCB, in delay of the disease
onset and increase of survival [22].
Here, we investigate if chronic administration of
AMD3100, a pharmacological antagonist of CXCR4, to
transgenic mice model of ALS (SOD1G93A) enables to
(1) regulate inflammatory response by reducing proin-
flammatory cytokines and microglial activation, (2) pre-
vent BSCB disruption, and if all together (3) may lead
to extension in mice lifespan and improved well-being.
Methods
Transgenic mice and treatment
We used transgenic mouse strain expressing mutant hu-
man SOD1 with the ALS-causing mutations: hemizygous
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SOD1G93A, which was maintained on a C57BL/6 congenic
background [26]. Fifty-, 70-, and 90-day-old female
SOD1G93A mice were injected subcutaneously with 5 mg
AMD3100 (Sigma-Aldrich, USA) or PBS (Biological In-
dustries, Israel) twice a week. Mice received the treatment
till the end stage of the disease, which was defined as the
point at which animals could not right themselves within
30 s after being placed on their side. At that point, mice
were euthanatized with Co2.. Other groups of 50-day-old
SOD1G93A mice and wild type littermate (LM) mice as
control were also treated with AMD3100 or PBS and
sacrificed at 110 days old via i.p anesthesia administration
of 100 mg/kg Ketamine (Fort Dodge, USA) and 20 mg/kg
Xylazine (Merck, Germany) following trans-cardial perfu-
sion with saline. The spinal cords that were collected from
the sacrificed mice served for biochemical (five mice in
each group) and histological analysis (three mice in each
group). The animals were in house maintained colony.
Mice were housed in standard conditions: constant
temperature (22 ± 1 °C), humidity (relative, 40 %), and a
12-h light/dark cycle and were allowed free access to food
and water. All of the animal experiments were conducted
in accordance with the Guide for the Care and Use of La-
boratory Animals and were approved by the Institutional
Animal Care and Use Committee of Tel Aviv University.
Clinical assessment
During the treatment period, mice were weighed and
their muscle strength and coordination deficits were
evaluated once a week using a Rotarod apparatus (rotat-
ing at an increasing speed ranging from 4–40 RPM, with
a constant acceleration of 1 RPM per 10 s). Mice were
trained on the machine for 3 days before the actual be-
ginning of the analysis. The time each mouse remained
on the drum was recorded, up to 300 s in each of the
three attempts made. Disease onset was determined as
the time animals reached their maximum bodyweight.
Tissue fractionation
SOD1G93A and LM mice were sacrificed at the age of
110 days, and samples of soluble and membrane enriched
fractions were prepared from spinal cord tissues. The tis-
sues were stored at −70 °C until homogenization. Tissues
were homogenized on ice in 5 volumes (w/v) of T-per
extraction buffer (Pierce, USA) complemented with prote-
ase inhibitor tablets (Complete Mini Protease Inhibitor
Tablets, Roche) and phosphatase inhibitor cocktail tab-
lets (phosSTOP, Roche). After sonication, the homoge-
nates were centrifuged at 100,000g for 1 h at 4 °C. The
resulting supernatants represent the soluble fraction.
The pellets were further resuspended in T-per extrac-
tion buffer complemented with protease and phosphat-
ase inhibitors as above, 0.5 % triton-100, 1 % sodium
deoxycholate, and 3 % SDS. The pellets were sonicated
and centrifuged at 10,000g for 1 h at 4 °C. Protein con-
centrations were determined using BCA protein assay
kit (Thermo, USA).
Western immunoblot analysis
Equal amounts of mice spinal cord homogenates protein
(40 μg) were resolved separately for soluble and mem-
brane fractions on SDS-PAGE, transferred to nitrocellu-
lose membrane, and blocked overnight with 5 % skim
milk in TBS-T (0.3 % Tween 20). Blots of the soluble
fraction were probed with the following primary anti-
bodies: mouse anti-actin (1:10,000 Sigma-Aldrich, USA),
rabbit anti-MCP-1 (1:1000 Peprotech, USA), rabbit
anti-IL-6 (1:1000 Peprotech, USA), and mouse anti-Iba-1
(1:1000 Millipore, Germany). Blots of the membrane
fraction were probed with the following primary anti-
bodies: mouse anti-actin (1:10,000 Sigma-Aldrich,
USA), rabbit anti-occludin (1:1000 Abcam, UK), rabbit
anti-claudin 5 (1:500, Sigma- Aldrich, USA), rabbit
anti-ZO-1 (1:1000 Sigma-Aldrich, USA), and rabbit
anti-cd36 (1:1000 Abcam, UK). Blots were incubated
with corresponding secondary antibodies conjugated
peroxidase (Sigma- Aldrich, USA) and developed with the
EZ-ECL detection kit (Biological Industries, Israel). Quan-
titative densitometric analysis was performed using the
densitometric software EZQuant-Gel (version 2.12).
TNF-α measurement
Soluble fraction of spinal cord homogenates, treated
with AMD3100 (n = 5) or PBS (n = 5), was subjected to
mouse TNF alpha ELISA Ready-SET-Go! kit, according
to the manufacturer’s instructions (eBioscience, USA).
Evans blue permeability assay
Fifty-day-old female SOD1G93A mice were treated with
AMD3100 (n = 3) or PBS (n = 3). On the age of
110 days, the mice were i.p injected with Evans blue
dye (50 μg/g body weight). Three hours post Evans blue
injection, the mice were anesthetized i.p with ketamine/
xylazine and perfused with saline. Spinal cords were
immersed in 500-μl formamide (Sigma- Aldrich, USA)
for 48 h at 60 °C to extract the dye, and its presence
was measured by OD620 [27].
Histological staining
A separate cohort of SOD1G93A mice treated with
AMD3100 (n = 3) or PBS (n = 3) at 50 days old was
sacrificed at 110 days old by i.p anesthesia with keta-
mine/xylazine and perfusion with saline. Their spinal
cords were harvested, fixed in 4 % (w/v) paraformalde-
hyde (PFA) in PBS (pH 7.4) and cryoprotected in 30 %
sucrose in PBS. Twenty-five-micro meter free-floating
cryosections were prepared from lumber spinal cords
and stained for Iba-1, hemosiderin deposits, IgG leakage,
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and thionin for motor neurons in lamina X. For all
histological stainings, 15 sections per group were used.
After staining, sections were dehydrated in graded alco-
hol, cleared in xylene and coverslipped with enthelan
(Merck, Germany). For Iba-1 staining, sections were
dried and coverslipped with mounting media containing
DAPI. Images were captured by a CCD color video cam-
era (ProgRes C14, Jenoptic, Jena, Germany) attached to
a Leica DMLB microscope (Leica, Germany) and ana-
lyzed with Image-J Software (NIH, freeware).
Iba-1 staining
Lumbar sections from SOD1G93A mice were blocked
with 0.3 % Triton + 0.2 % goat serum for 1 h and incu-
bated over night at 4 °C with 1:500 Iba-1 (Abcam, UK).
On the next day, the sections were incubated with anti-
rabbit Alexa 546 (Invitrogen, USA) for 2 h, air-dried,
and coverslipped with mounting medium with DAPI
(Abcam, UK) [28].
Prussian blue staining
Lumbar sections from SOD1G93A mice were incubated
in a 5 % potassium ferrocyanide and 5 % hydrochloric
acid solution (1:1 working solution) for 30 min. The sec-
tions were then washed and subsequently counterstained
with nuclear fast-red. Hemosiderin shows blue, the nu-
clei shows red, whereas the cytoplasm shows pink. To
access the relative abundance of Prussian blue-positive
deposits per section, we divided total numbers of
Prussian blue-positive spots by the number of studied
sections [23].
IgG leakage staining
Serum protein leakage (IgG) was assessed by Vectastain
ABC kit (Vector Laboratories) according to the manu-
facturer’s instructions. Briefly, sections were treated with
3 % H2O2 in absolute methanol for 25 min, blocked by
horse serum for 1 h at room temperature, and incubated
with biotynilated secondary antibody for 1 h and avidin
HRP for 30 min. The reaction product was visualized
using DAB chromogen substrate (Invitrogen, USA).
Nissl stain for motor neurons
Nissl bodies were stained with 0.1 % thionin. Results of
motor neurons were expressed as the average of total
motor neurons counted per section [29].
Statistical analysis
Survival and disease onset were analyzed using the
Kaplan-Meier with log-rank (Mantel-Cox) test. Weight,
behavioral analysis, histochemistry, and biochemistry
were presented as the mean ± SEM and subjected to un-
paired one-tailed Student’s t tests. *p < 0.05; **p < 0.01
was considered statistically significant.
Results
In this study, we examined the ability of the CXCR4 an-
tagonist, AMD3100, to affect microglial pathology and
BSCB integrity towards extended lifespan of transgenic
mice model of ALS. The SOD1G93A mice model of ALS
used in this study expresses gradual upper and lower
motor neurons death, leading to impaired motor func-
tion and death, representing a close model of disease
progression in humans. Female SOD1G93A mice were
administered subcutaneously with 5 mg AMD3100 at
50 days old, twice a week. Mice body weight and their
motor function, evaluated by Rotarod test, was recorded
once a week. A similar therapeutic protocol was applied
on another group of SOD1G93A mice, also starting at
50 days old and sacrificed at 110 days old for biochem-
ical and histological analysis of relevant markers.
Survival experiments starting at 50 days old to
SOD1G93A mice were performed for both male and fe-
male mice, showing the same trend. The biochemical
and histological analyses were chosen to be performed
only in females rather than males, due to the fact that
this model is less aggressive in females [30], making it
more plausible to detect AMD3100’s effect on the dis-
ease. Moreover, the mechanism of inhibition for
AMD3100 is expected to be the same in both genders
and is expected to act in the same manner in both
genders. Survival plot for male mice is presented in
Additional file 1.
AMD3100 decreases microglial inflammation levels
of treated mice
Inflammation in the central nervous system is a com-
mon clinical feature in ALS patients and animal models
[31]. Activated microglia and its cytotoxic microglial
markers, including TNF-α and IL-6 cytokines, Iba-1 and
cd36 markers [2, 3, 32, 33], precede astrocyte reactivity
[34] and show reduced neuroprotective behavior of
mSOD1 microglia [2, 3].
Indeed, TNF-α levels were significantly reduced in
spinal cords of SOD1G93A mice treated with AMD3100,
visualized by ELISA kit (Fig. 1a). IL-6 levels were also
significantly decreased as visualized by western blot ana-
lysis (Fig. 1b), however, in a lower extent than TNF-α.
The activated microglial markers Iba-1 (Fig. 1c) and
cd36 (Fig. 1e) were significantly decreased as well in
treated SOD1G93A mice, visualized by western blot ana-
lyses. Immunhistochemical staining of Iba-1 showed the
same trend as the immunoblot of this marker (Fig. 1d).
AMD3100 treatment decreases BSCB permeability
and increases tight junction proteins levels
Evaluation of BSCB permeability was performed by Evans
blue permeability assay and histological staining of hemo-
siderin deposits and IgG localization. SOD1G93A mice
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treated with AMD3100 showed significantly less positive
Evans blue dye in their spinal cords (Fig. 2a), compared
with mice treated with PBS, as well as reduced hemo-
siderin deposits (Fig. 2b) and reduced IgG leakage
levels (Fig. 2c).
ALS-linked SOD1 mutant mice are known to reduce
the levels of three major tight junction proteins between
endothelial cells, including occludin, claudin-5, and
ZO-1, thus disrupting the BSCB integrity [23]. Treat-
ment with AMD3100 increased the levels of all three
markers in SOD1G93A (Fig. 2d–f ).
MCP-1 is involved in recruiting monocytes and mac-
rophages to the CNS [35]. However, a growing body of
evidence implicates MCP-1 as an angiogenic factor as
well, being responsible for brain permeability, by affect-
ing the permeability of endothelial cells [36]. Western
blot analysis of SOD1G93A mice treated with AMD3100
showed significant reduction in MCP-1 levels, com-
pared with PBS-treated mice (Fig. 2g).
AMD3100 increases number of motor neurons in the
ependymal layer within lamina X of the spinal cord
Adult stem cells in the spinal cord appear in the epen-
dymal layer within lamina X around the central canal
[37]. Administration of AMD3100 to SOD1G93A mice
starting at 50 days old, significantly increased the num-
ber of motor neurons in the lamina X, as observed by
thionin staining (Fig. 3).
AMD3100 extends significantly SOD1G93A mice lifespan
and disease onset and improves significantly the weight
loss and motor function
Starting at 50 days old, female SOD1G93A mice were
treated subcutaneously with 5 mg AMD3100 or PBS
Fig. 1 AMD3100 decrease microglial inflammatory markers and proinflammatory markers. SOD1G93A and LM mice were treated with AMD3100 or
PBS and sacrificed at 110 days old, and the levels of activated microglia markers were measured. Five mice in each treatment group of SOD1G93A
and LM mice were tested. a TNF-α level in spinal cord homogenates of SOD1G93A mice were measured using ELISA kit. (TNF-α for PBS is 43.77 pg/ml,
for AMD3100 is 15.45 pg/ml) b IL-6 levels of SOD1G93A mice measured via western blot analysis. c Iba-1 levels of SOD1G93A mice measured via western
blot analysis. d Immunohistochemical staining of Iba-1. e cd36 levels of SOD1G93A mice measured via western blot analysis. Results are mean ± S.E.M.,
*p < 0.05, **p < 0.01
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twice a week. Mice received continuous treatment until
the end stage of disease. Treatment with AMD3100
significantly extended the survival of SOD1G93A mice.
Median survival of PBS-treated SOD1G93A mice was
131 days (n = 13), whereas treatment with AMD3100
increased the lifespan of SOD1G93A mice to 144 days
(n = 22) (p < 0.0001, Mantel-Cox test), an increase of
13 days (Fig. 4a). Furthermore, treatment with
AMD3100 significantly delayed disease onset (Fig. 4d),
determined as the time animals reached their max-
imum bodyweight. Disease progression and mice well-
being were monitored weekly by weight record and
motor performance by Rotarod. AMD3100 treatment
resulted in significant slowdown in weight loss (Fig. 4e)
and significant improvement in Rotarod performance
(Fig. 4f ).
AMD3100 treatment extends survival of 70 days old mice,
but not the onset, whereas treatment at 90 days old has
no beneficial effect
In order to assess the effect of AMD3100 on later stages
of the disease, 70- and 90-day-old female SOD1G93A
mice were treated subcutaneously with 5 mg AMD3100
or PBS twice a week. Treatment at 70 days old signifi-
cantly increased lifespan of mice by 12 days (p =
0.0025, Mantel-Cox test). Median survival of PBS-
treated SOD1G93A mice was 149 days (n = 7), whereas
treatment with AMD3100 increased the lifespan of
Fig. 2 AMD3100 reduces BSCB permeability and increases tight junction proteins levels. a Evans blue permeability assay. Fifty-day-old SOD1G93A
mice were treated with AMD3100 (n = 3) or PBS (n = 3). One hundred ten-day-old mice were IP injected with Evans blue dye (50 ug/g body weight).
Three hours post injection mice were sacrificed and perfused, and dye presence in the spinal cord was measured as ratio of tissue weight. b Regional
analysis of hemosiderin deposits. c IgG leakage in the lumbar cord anterior horn of SOD1G93A mice treated with AMD3100 (n = 3) or PBS (n = 3) from
50 to 110 days old. Fifteen nonadjacent sections were examined for each treatment group. d Occludin levels of SOD1G93A mice. e Claudin-5 levels of
SOD1G93A mice. f ZO-1 levels of SOD1G93A mice. g MCP-1 levels of SOD1G93A mice. For tight junction proteins, SOD1G93A mice were treated with
AMD3100 or PBS and sacrificed at 110 days old, and protein levels were measured using western blot. Five mice in each treatment group of SOD1G93A
mice were tested. Results are mean ± S.E.M., *p < 0.05, **p < 0.01
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SOD1G93A mice to 161 days (n = 10) (Fig. 5a). No sig-
nificant effect on disease onset (Fig. 5b) was observed.
Whereas treatment at 50 and 70 days old increased
SOD1G93A mice lifespan, treatment at the late stage of
disease, 90 days old, had no effect on survival (Fig. 5c)
and disease onset (Fig. 5d). Since treatments at 70 and
90 days old had no significant effect on weight changes
and motor function, the biochemical and histological
analyses were performed only on female SOD1G93A
mice treated with AMD3100 at 50 days old.
Discussion
Inflammation abnormalities are considered to be highly
involved in the neuropathology of ALS. At sites of
motor neuron injury, neuroinflammation is a promin-
ent pathological finding characterized by microglial
Fig. 4 AMD3100 administration significantly extended 50 days old SOD1G93A mice survival and delayed the disease onset. a Survival of mice
treated with AMD3100 (n = 22) and PBS (n = 13) was defined as the point at which animals could not right themselves within 30 s after being
placed on their side. Mantel-Cox test; p < 0.0001. b Median survival of mice demonstrates 13 days increase in lifespan. c Maximum survival of
mice. d Disease onset was determined as the time animals reached their maximum bodyweight. Mantel-Cox test; p = 0.0036 e Weight change
monitored weekly. f Motor function assessed weekly by Rotarod test. Results are mean ± S.E.M., *p < 0.05, **p < 0.01
Fig. 3 Increase in the number of motor neurons in lamina X following AMD3100 treatment. SOD1G93A mice were treated with AMD3100 (n = 3)
or PBS (n = 3) starting at 50 days old and sacrificed at 110 days old. Fifteen nonadjacent sections per group of lumbar spinal cords were stained
with thionin and analyzed within the lamina X zone of central canal. Results are mean ± S.E.M., *p < 0.05
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activation, astrogliosis, and infiltration of monocytes
and T cells [2, 3]. A study by Hensley et al. suggested
that TNF-α, IL6, and IFN cytokines synergize to pro-
duce disproportionate microglial activation in the de-
generating spinal cord. Moreover, TNF-α alone is a
potent stimulant for generating reactive nitrogen spe-
cies (RNS) and its effects are strongly amplified by the
presence of IL-6 or IFN [38]. Evidence for TNF-α in-
volvement in ALS is also supported by high levels of
circulating TNF-α and its soluble receptors in ALS
patients [39]. This elevation in TNF-α levels may be
facilitated by the activation of the CXCR4 pathway on
glial cells. Binding of CXCL12 to CXCR4 leads to the
downstream release of TNF-α from cell surface. TNF-α
then binds to its receptor, TNFR1, on the glial mem-
brane, and in turn triggers glutamate release that even-
tually leads to neuronal death [40]. Following the
downstream activation of the CXCR4 pathway, it can
be assumed that inhibition of CXCR4 by AMD3100
may reduce TNF-α levels. Indeed, we demonstrated
that chronic administration of AMD3100 to SOD1G93A
mice led to a significant decrease in TNF-α levels in
the soluble fraction of spinal cords.
IL-6 is also increased in CSF, serum, and skin of ALS
patients [41, 42]. The transcriptional regulation of IL-6 is
mediated by phosphorylation of ERKs and binding of
nuclear factor-kappa B (NF-kB) to the IL-6 promoter. This
pathway is enhanced by CXCL12 [43]. Recently, it was
reported that treatment with AMD3100 after experimen-
tal stroke reduce IL-6 levels as well as other proinflamma-
tory cytokines [44]. In agreement with these findings, our
results show that chronic treatment with AMD3100 sig-
nificantly reduced IL-6 levels in SOD1G93A mice.
Microglial activation was suggested to precede astro-
cyte reactivity and correlates with disease progression
[34]. Activation of microglia may be observed through
the up-regulation of Iba1 and cd36 markers [3, 32].
AMD3100 treatment, starting at 50 days, significantly
attenuated microglial activation of SOD1G93A mice, ob-
served by reduced protein levels of Iba1 and cd36 in
both western blot and immunohistochemical staining.
The fact that no effect on the microglial markers was
observed in LM mice suggests that this effect is specific
to neuropathological processes of disease progression
(Additional file 2). Astrocytic markers including GFAP
and S100B were not changed in SOD1G93A mice follow-
ing AMD3100 treatment (Additional file 3).
Accumulating reports state that increased permeability
of the BSCB is also involved in motor neuron degener-
ation and the pathogenesis of ALS. Recent works have
strongly confirmed this observation in both human ALS
patients [45–47] and SOD1 mutant animals [23, 25, 48].
Fig. 5 AMD3100 administration had little effect on 70- and 90-day-old SOD1G93A mice survival and disease onset. a Survival of mice treated with
AMD3100 (n = 10) and PBS (n = 7) at 70 days old. Mantel-Cox test; p = 0.0025. b Disease onset of mice treated at 70 days old. c Survival of mice
treated with AMD3100 (n = 9) and PBS (n = 10) at 90 days old. d Disease onset of mice treated at 90 days old
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Here, we show that AMD3100 treatment to SOD1G93A
mice led to a significant increase in the expression of
tight junction proteins occludin and claudin-5. These
findings are further supported by reduction in Evans
blue extravasation, decreased hemosiderin deposits, and
IgG leakage into the spinal cord. Combined, these re-
sults indicate that AMD3100 treatment attenuates the
breakdown of BSCB integrity, associated with ALS path-
ology, and reduces its permeability.
The effect on BSCB integrity is also accompanied by a
significant reduction in MCP-1 levels in treated spinal
cords. Since CCR2, the receptor for MCP-1, is expressed
by endothelial cells, it has been suggested that MCP-1,
on top of being an inflammatory marker, has additional
functions related to endothelial cells, such as redistribut-
ing the tight junction proteins occludin, claudin-5, and
ZO-1 [36]. Indeed, Zhong et al. showed that MCP-1
levels are increased at symptomatic and end stage of dis-
ease, when the BSCB is already disrupted in animal mu-
tant SOD1 mice.
The three tight junction proteins, occludin, claudin-5
and ZO-1, as well as MCP-1 levels were evaluated in
LM-treated mice as well (Additional file 4). This effect
of AMD3100 on BSCB permeability of LM might have
potential therapeutic effect in other diseases involving
BSCB breakdown.
To further stress the multifaceted mechanism of
AMD3100, the observed reduction in microglial markers
by AMD3100 treatment may have resulted from (1) at-
tenuated infiltration of peripheral cells into the CNS, as
BSCB permeability was repaired, (2) reduced infiltration
of monocytes/macrophages productions independent of
microglia, and (3) AMD3100 suppressed both microglia
and macrophage (and/or other infiltrating cell) inflamma-
tory cytokine production.
Spinal cord disorders are characterized by an increase in
proliferation of neural progenitor cells (NPC) but preferen-
tially differentiate into glial cells rather than neurons [49].
Thus, in order to enhance NPC proliferation towards neu-
rons, further stimuli should be introduced. A recent study
provided such stimulus by lithium administration to
SOD1G93A mice. It showed an increase in motor neurons
count in the lamina X region, which possesses a stem cell-
like activity [29]. In the current study, we demonstrated
that AMD3100 treatment resulted in significant in-
crease in motor neurons counts in the lamina X area.
Moreover, increase in the number of motor neurons in
all area of the spinal cord sections was also observed
but was not statistically significant (Additional file 5).
To summarize, three different groups of mice were
treated with 5 mg AMD3100, starting at 50, 70, and
90 days old. The best improvement in all parameters, in-
cluding the clinical signs (weight loss and motor function)
was observed at the earliest point of treatment, 50 days
old. Treatment at 70 days old followed the same survival
rate as 50 days old mice; however, it did not show the
same improvement in clinical signs. Starting treatment at
90 days old mice had no clinical benefits whatsoever.
These results stress the importance of early detection in
ALS patients for AMD3100 treatment to be effective. For
maximal benefits from AMD3100 treatment, appropriate
diagnosis of ALS at early stages must be developed.
Conclusions
Here, we show that chronic administration of AMD3100
to transgenic mice model of ALS (SOD1G93A) has a sub-
stantial clinical feature via restoration of levels of tight
junction proteins that are essential for BSCB integrity
and reduction of inflammation, leading to significant in-
crease in survival of treated mice. The data presented
here, relevant to the corresponding disease mechanism
in humans, implicates AMD3100 as a possible candidate
for ALS therapy with a multifaceted effect. As soon as a
full understanding of its effects is reached, treatment
based on this agent can move forward relatively fast in
the pipeline, as AMD3100 was found safe and approved
by the FDA for other indications.
Additional files
Additional file 1: AMD3100 administration significantly extended 50
days old SOD1G93A mice survival males. Survival of mice treated with
AMD3100 (n=12) and PBS (n=12) was defined as the point at which
animals could not right themselves within 30 sec after being placed on
their side. Mantel-Cox test; p < 0.0001. (TIF 91 kb)
Additional file 2: AMD3100 does not affect microglial inflammatory
markers and proinflammatory markers in LM. LM mice were treated with
AMD3100 or PBS, sacrificed at 110 days old, and levels of activated microglia
markers were measured. Five mice in each treatment group of SOD1G93A
and LM mice were tested. a. TNF-α level in spinal cord homogenates of
SOD1G93A mice were measured using ELISA kit. b. IL-6 levels of SOD1G93A
mice measured via western blot analysis. c. Iba-1 levels of SOD1G93A mice
measured via western blot analysis. d. cd36 levels of SOD1G93A mice
measured via western blot analysis. Results are mean ± S.E.M. (TIF 87 kb)
Additional file 3: Astrocytic markers including GFAP and S100B were
not changed in SOD1G93A mice following AMD3100 treatment. SOD1G93A
mice were treated with AMD3100 or PBS, sacrificed at 110 days old, and
levels of astrocytes markers were measured. Five mice in each treatment
group of SOD1G93A and PBS were tested. a. GFAP levels of SOD1G93A
mice measured via western blot analysis. b. S100B levels of SOD1G93A
mice measured via western blot analysis. Results are mean ± S.E.M.
(TIF 38 kb)
Additional file 4: AMD3100 increases tight junction proteins levels in
LM. For tight junction proteins LM mice were treated with AMD3100 or
PBS, sacrificed at 110 days old, and protein levels were measured using
western blot. Five mice in each treatment group of SOD1G93A mice were
tested. a. occludin levels of LM mice. b. claudin-5 levels of LM mice. c.
ZO-1 levels of SOD1G93A mice. d. MCP-1 levels of SOD1G93A mice. Results
are mean ± S.E.M, *p < 0.05. (TIF 85 kb)
Additional file 5: Increase in the number of motor neurons in spinal
cords of AMD3100 following treatment. SOD1G93A mice were treated
with AMD3100 (n=3)or PBS (n=3) starting at 50 days old and sacrificed at
110 days old. Fifteen nonadjacent sections per group of lumbar spinal
cords were stained with thionin and analyzed. Results are mean ± S.E.M.
(TIF 191 kb)
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